Health & Fitness
Mon, January 9, 2012Sun, January 8, 2012Sat, January 7, 2012Fri, January 6, 2012Thu, January 5, 2012Wed, January 4, 2012Tue, January 3, 2012Mon, January 2, 2012Sat, December 31, 2011Fri, December 30, 2011Thu, December 29, 2011Wed, December 28, 2011Tue, December 27, 2011Mon, December 26, 2011Fri, December 23, 2011Thu, December 22, 2011Wed, December 21, 201130 a.m. Eastern Time to Discuss Ongoing Patent Litigation
Published in Health and Fitness on Monday, January 2nd 2012 at 14:27 GMT by Market Wire
Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern... -- TARRYTOWN, N.Y., Jan. 2, 2012 /PRNewswire/ --
Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
TARRYTOWN, N.Y., Jan. 2, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: [ REGN ]) today announced that it will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. Eastern Time to provide an update on the status of the ongoing patent litigation with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY).
Conference Call Information
Domestic Dial-in Number: (888) 660-6127
International Dial-in Number: (973) 890-8355
Participant Code: 40392582
An archived version of the conference call will be available for 30 days on the company's website at [ www.regeneron.com ] on the Investor Relations page.
About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection. Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].
Contact Information: |
|
|
|
Michael Aberman, M.D. | Peter Dworkin |
Investor Relations | Corporate Communications |
914.847.7799 | 914.847.7640 |
SOURCE Regeneron Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.regeneron.com ]
